Skip to content
International Academy for Clinical Hematology (IACH) Logo
  • About
    • Mission
    • Bylaws
    • Topics
    • Membership
    • Founders
    • Conflict of Interest Policy
    • Clinical Hematology International
    • IACH Supporters
    • Terms of Service
    • Contact
  • Meetings
    • Controversies in Multiple Myeloma (COMy)
    • Controversies in MDS and AML (COMydAL)
    • Controversies in Lymphoma (COLYM)
    • MPNControversies & Debates (MPN Co&D)
    • Annual Meeting of the IACH
    • Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
  • Webinars
    • Webinars
    • Post-Cong. webinars
    • Special webinars
  • IACH for Nurses
  • Journal Club
  • Junior Club
  • IACH Special Events
    • IACH Giants
    • IACH CAR-T News
    • The Innovation and R&D Podium
  • IACH News (Podcasts)

Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

  1. Home
  2. All
  3. Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Previous Next

Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

By efrat|2022-10-24T08:28:01+00:00October 24th, 2022|All|Comments Off on Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: efrat

Related Posts

Sept 19th 2023- Prof. Ephraim Fuchs- Cytokine Release Syndrome in Haploidentical Stem Cell Transplant May Impact T-cell Recovery and Relapse

Sept 19th 2023- Prof. Ephraim Fuchs- Cytokine Release Syndrome in Haploidentical Stem Cell Transplant May Impact T-cell Recovery and Relapse

Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report

Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report

Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study

Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study

Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions

Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions

Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL

Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL

About

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology, is registered in England (Number: 14200227) under the Companies Act 2006.

In collaboration with:

Contact

International Academy for Clinical Hematology (IACH)
35 Ballards Lane
London N3 1XW
United-Kingdom
info@clinical-hematology.org
+44 203 291 1603
IACH on Twitter
IACH on LinkedIn

Copyright © 2022 International Academy for Clinical Hematology | All Rights Reserved
Page load link
Go to Top